Insider buying is spurring momentum in these two biotech companies. One is a “buy now”, and the other is a “buy on a pullback.”
EPIRUS Biopharmaceuticals, Inc. (EPRS)
from Cotton’s Technically Speaking
On February 4, 2015, EPIRUS Biopharmaceuticals, Inc. (EPRS) insiders Scott Rocklage, and 5AM Partners III, LLC bought 400,000 shares of their company’s stock at a price of $5.00 for a total of $2,000,000 each. I bought it because the chart looked great, and the stock was selling at an historical low price and it had great drugs in its pipeline. The stock doubled within one month, but I expect it to go a lot higher.
Joseph Cotton, Cotton’s Technically Speaking, www.cottonstocks.net, 727-289-4436, May 6, 2015